Sphaera Pharma Pte. Ltd.

Locus Pharmaceuticals, Inc.

Speedel Experimenta Ag

Frank Peter Hollinger

Sundeep Dugar

Dinesh Mahajan

Zenon D Konteatis

Jennifer Lee Ludington

Bruce D Dorsey

Peter Herold

Robert Mah

Stefan Stutz

Enrique Luis Michelotti

Vincenzo Tschinke

Bin Liu

Aleksandar Stojanovic

Christiane Marti

Dirk Behnke

Michael Siegfried Quirmbach

Stjepan Jelakovic

Rupa S Shetty

William Chiang

Duyan Nguyen

Kamal Kishore Kapoor

Younghee Lee

Rhushikesh Chandrabhan Deokar

Kristofer K Moffett

Eric Bruce Springman

Stephan Brunner

David Mosenkis

Ted Tsutomis Fujimoto

Chandraban Rhushikesh Deokar

The present invention discloses novel chemical compounds obtained by causing a covalent attachment of a modifying agent of the structure provided for formula 1, to a functional group or a heteroatom of a heterocyclic ring system in chemical compound with improved chemical and biological properties. Wherein: Y is DRUG-CO; DRUG-OCO; DRUG-NRCO, and X is selected from.

Compounds, their synthesis and their uses

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/or the mTOR pathway.

Triazine compounds

The present invention relates to the synthesis and application of novel chiral/achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.

Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds

The present invention is directed to a compound having the formula wherein R, R, G, and Q are defined herein. The compounds of the present invention are useful as inhibitors of protein kinases such as MAP kinases, in particular p38 kinases. The present invention is also directed to compositions comprising a compound according to the above formula. The compounds and compositions described herein are useful for treating and preventing an inflammatory condition or disease. The present invention is also directed to a method of treating or preventing a protein kinase-mediated condition.

Urea inhibitors of MAP kinases

Substituted piperidines of formulae (I) and (II) with the substituent definitions as explained in the specification. The compounds are suitable in particular as renin inhibitors and are highly potent. 

Substituted piperidines

A method implemented in the form of a computer simulation code for evaluating the free energy of binding between polypeptide amino acid residues and one or more molecular fragment types is presented. The basis of the method is a novel weighted Metropolis Monte Carlo approach for sampling the grand canonical ensemble. By making use of the properties of the grand canonical ensemble, the affinity of fragments for binding in the vicinity of each protein residue can be efficiently computed. The binding volume associated to each fragment-residue pair is estimated on the basis of a simple proximity criteria, and a useful affinity mapping of the protein surface can be obtained in this way. The analysis of such data for various fragment types provides valuable information to help identify protein binding sites, as well as to identify key fragments used for building potential drug leads.

Methods and systems for analyzing and determining ligand-residue interaction

Growing community of inventors

Wayne, PA, United States of America

Frank Peter Hollinger